14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CRMG vs ACET: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Adicet Bio, Inc. (ACET) is the stronger overall head-to-head candidate over Leverage Shares 2X Long CRM Daily ETF (CRMG) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CRMG carries a Unified Composite Score of 63.5/100 (BUY) at $6.72 (N/M Forward P/E, N/A operating margin), whereas ACET carries 43.8/100 (HOLD) at $2.63 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While CRMG currently prints a higher short-term Unified Composite Score (63.5/100 BUY vs. ACET 43.8/100 HOLD), ACET captures the overall institutional head-to-head verdict (6–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (-100.0% vs. N/A YoY).
Technical & Structure Timing Caution: CRMG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.8); meanwhile ACET is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 16.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRMG vs ACET. Trailing 12-month operating profitability (CRMG N/A vs ACET 0.0%) and valuation multiples (CRMG N/M vs ACET N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $27.4M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CRMG vs ACET Key Questions & Quantitative Answers
As of Nov 16, 2026, Adicet Bio, Inc. (ACET) is the stronger overall head-to-head candidate over Leverage Shares 2X Long CRM Daily ETF (CRMG) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CRMG carries a Unified Composite Score of 63.5/100 (BUY) at $6.72 (N/M Forward P/E, N/A operating margin), whereas ACET carries 43.8/100 (HOLD) at $2.63 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While CRMG currently prints a higher short-term Unified Composite Score (63.5/100 BUY vs. ACET 43.8/100 HOLD), ACET captures the overall institutional head-to-head verdict (6–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (-100.0% vs. N/A YoY). Technical & Structure Timing Caution: CRMG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.8); meanwhile ACET is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 16.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ACET leads the Growth & Scale pillar: CRMG posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ACET at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CRMG generates N/A in USD-normalized revenue versus N/A for ACET. In operating R&D and SG&A reinvestment, CRMG deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ACET.
ACET screens cheaper on headline valuation multiples. CRMG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ACET trades at N/M Forward P/E, N/M Trailing P/E, 0.82x PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRMG (N/A ROE) versus ACET (-78.1% ROE) capital efficiency.
In options market volatility and institutional positioning, CRMG carries 107.3% implied volatility (39th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.46β · 61% Vol realized risk). By comparison, ACET carries 84.5% implied volatility (6th %ile, Compressed (<25th %ile)), a 1.22x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.87β · 44% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.